Year archive

ViroGates A/S — 2021 filings

All 39 regulatory filings released by ViroGates A/S (VIRO) in 2021, sourced directly from the official regulator.

39 Filings

2021 Period

2021 filings (39)

Filing	Released	Lang
ViroGates announces a positive opinion from the CHMP of the EMA for suPAR-guided anakinra treatment of patients with COVID-19 pneumonia Regulatory Filings	2021-12-16	English
ViroGates announces a positive opinion from the CHMP of the EMA for suPAR-guided anakinra treatment of patients with COVID-19 pneumonia Regulatory Filings	2021-12-16	English
ViroGates announces a development, supply and collaboration agreement with Italy-based DIESSE for adaption of suPARnostic® ELISA on the Chorus Trio platform Regulatory Filings	2021-12-09	English
ViroGates announces a development, supply and collaboration agreement with Italy-based DIESSE for adaption of suPARnostic® ELISA on the Chorus Trio platform Regulatory Filings	2021-12-09	English
ViroGates awarded a 2.8 DKKm Innobooster grant by The Innovation Fund Denmark to finalize the development of the suPARnostic® POC+ product Regulatory Filings	2021-12-09	English
ViroGates awarded a 2.8 DKKm Innobooster grant by The Innovation Fund Denmark to finalize the development of the suPARnostic® POC+ product Regulatory Filings	2021-12-09	English
ViroGates awarded a 2.8 DKKm Innobooster grant by The Innovation Fund Denmark to finalize the development of the suPARnostic® POC+ product Regulatory Filings	2021-12-06	English
ViroGates announces a development, supply and collaboration agreement with Italy-based DIESSE for adaption of suPARnostic® ELISA on the Chorus Trio platform Regulatory Filings	2021-12-06	English
ViroGates announces a delay in the development and launch of its pipeline product suPARnostic® POC+ Regulatory Filings	2021-11-11	English
ViroGates announces a delay in the development and launch of its pipeline product suPARnostic® POC+ Regulatory Filings	2021-11-11	English
ViroGates announces a new hospital as a clinical routine customer in Greece Regulatory Filings	2021-10-26	English
ViroGates announces a new hospital as a clinical routine customer in Greece Regulatory Filings	2021-10-26	English
ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19 Director's Dealing	2021-09-03	English
ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19 Director's Dealing	2021-09-03	English
ViroGates announces its Half-Year Report for H1 2021: Increasing clinical revenue and positive topline results from COVID-19 clinical trial Interim / Quarterly Report H1 2021	2021-08-19	English
ViroGates announces its Half-Year Report for H1 2021: Increasing clinical revenue and positive topline results from COVID-19 clinical trial Report Publication Announcement H1 2021	2021-08-19	English
ViroGates announces its Half-Year Report for H1 2021: Increasing clinical revenue and positive topline results from COVID-19 clinical trial Report Publication Announcement H1 2021	2021-08-19	English
ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19 Director's Dealing	2021-06-11	Danish
ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19 Director's Dealing	2021-06-11	English
ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19 Director's Dealing	2021-06-01	Danish
ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19 Director's Dealing	2021-06-01	Danish
ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19 Director's Dealing	2021-06-01	English
ViroGates announces its first clinical routine customer in Italy Regulatory Filings	2021-05-28	English
ViroGates announces its first clinical routine customer in Italy Regulatory Filings	2021-05-28	English
ViroGates announces a capital increase in connection with the exercise of warrants Share Issue/Capital Change	2021-05-21	English
ViroGates announces a capital increase in connection with the exercise of warrants Share Issue/Capital Change	2021-05-21	English
ViroGates reports use of suPAR-guided anakinra treatment improved overall clinical outcome by 64% in hospitalised patients with COVID-19 pneumonia Regulatory Filings	2021-05-03	English
ViroGates reports use of suPAR-guided anakinra treatment improved overall clinical outcome by 64% in hospitalised patients with COVID-19 pneumonia Regulatory Filings	2021-05-03	English
ViroGates announces its Annual Report 2020: Growing revenue and customer base - a robust platform for the future Report Publication Announcement FY 2020	2021-03-24	English
ViroGates announces its Annual Report 2020: Growing revenue and customer base - a robust platform for the future Report Publication Announcement	2021-03-24	English
ViroGates announces its Annual Report 2020: Growing revenue and customer base - a robust platform for the future Report Publication Announcement FY 2020	2021-03-24	English
ViroGates announces CE-IVD approval for suPARnostic® TurbiLatex on the Abbott Alinity platform Regulatory Filings	2021-03-15	English
ViroGates announces CE-IVD approval for suPARnostic® TurbiLatex on the Abbott Alinity platform Regulatory Filings	2021-03-15	English
ViroGates announces a new clinical routine customer in Greece Regulatory Filings	2021-03-03	English
ViroGates announces a new clinical routine customer in Greece Regulatory Filings	2021-03-03	English
ViroGates announces a new private hospital as clinical routine customer in Spain Regulatory Filings	2021-02-02	English
ViroGates announces a new private hospital as clinical routine customer in Spain Regulatory Filings	2021-02-02	English
ViroGates announces initiation of a clinical trial with HISS to clinically validate its commercial biomarker test for guiding early anakinra treatment of COVID-19 patients across 42 hospitals Regulatory Filings	2021-01-26	English
ViroGates announces initiation of a clinical trial with HISS to clinically validate its commercial biomarker test for guiding early anakinra treatment of COVID-19 patients across 42 hospitals Regulatory Filings	2021-01-26	English